Did You Invest in Gilead Sciences?

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nov 08, 2019 08:06 pm
OAKLAND, Calif. -- 

The U.S. Government has filed a lawsuit accusing Gilead Sciences of violating patents owned by the U.S. Department of Health and Human Services related to Truvada, Gilead’s HIV prevention drug. Gibbs Law Group has launched a Gilead Sciences Investor Lawsuit investigation on behalf of those who invested in Gilead Sciences (NASDAQ: GILD).

To speak with an attorney regarding this lawsuit investigation, click here or call (888) 410-2925.

On November 6, 2019, the U.S. Department of Health and Human Services filed a lawsuit against Gilead Sciences, accusing the company of infringing on government patents on Truvada, and the concept of “PrEP,” or pre-exposure prophylaxis, which can prevent H.I.V. with a daily pill.

The lawsuit specifically alleges that CDC researchers began studying the preventive use of HIV treatment drugs — like tenofovir, or TDF, and emtricitabine, FTC, the two compounds in a Truvada tablet — as early as 1998, before Gilead sought a patent.

In a statement about the patent lawsuit, Alex Azar II, the secretary of the Department of Health and Human Services stated:

“Gilead must respect the U.S. patent system, the groundbreaking work by researchers with the Centers for Disease Control and Prevention, and the substantial taxpayer contributions to the development of these drugs.”

What Should Gilead Sciences Investors Do?

If you invested in Gilead Sciences, you may have legal claims. Visit our website or contact our securities team directly at (888) 410-2925 to discuss your possible legal options. Our investigation concerns whether Gilead Sciences and certain of its officers and/or directors have violated federal securities laws.

About Gibbs Law Group

Gibbs Law Group represents individual and institutional investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Top Class Action Attorneys Under 40,” “Consumer Protection MVP,” and “Top Cybersecurity/ Privacy Attorneys Under 40.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

PHONE: 510.350.9728
EMAIL: [email protected]

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).